StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $8.00 | $7.60 | -5.00% | 0.2M |
| 05-19 | $7.52 | $8.46 | +12.50% | 0.1M |
| 05-20 | $8.28 | $8.12 | -1.93% | 0.1M |
| 05-21 | $8.01 | $8.23 | +2.75% | 0.0M |
| 05-22 | $8.35 | $8.36 | +0.12% | 0.0M |
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2020 2020-06-30 |
|---|---|
Revenue | $31.00K |
Operating Income | $-9.51M |
Net Income | $-9.79M |
EPS (Diluted) | $-0.68 |
Total Assets | $49.46M |
Total Liabilities | $19.82M |
Cash & Equivalents | $19.79M |
Free Cash Flow OCF − CapEx | $-8.46M |
Shares Outstanding | 18.64M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.